- Home
- TRUG vs TNXP Comparison
TRUG vs TNXP Comparison
Compare TRUG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- TNXP
- Stock Information
- Founded
- TRUG 1983
- TNXP 2007
- Country
- TRUG United States
- TNXP United States
- Employees
- TRUG N/A
- TNXP N/A
- Industry
- TRUG
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- TNXP Health Care
- Exchange
- TRUG NYSE
- TNXP Nasdaq
- Market Cap
- TRUG 9.1M
- TNXP 19.5M
- IPO Year
- TRUG N/A
- TNXP N/A
- Fundamental
- Price
- TRUG $0.43
- TNXP $0.61
- Analyst Decision
- TRUG Strong Buy
- TNXP Strong Buy
- Analyst Count
- TRUG 1
- TNXP 2
- Target Price
- TRUG $2.00
- TNXP $53.50
- AVG Volume (30 Days)
- TRUG 11.9M
- TNXP 202.6M
- Earning Date
- TRUG 02-12-2025
- TNXP 11-12-2024
- Dividend Yield
- TRUG N/A
- TNXP N/A
- EPS Growth
- TRUG N/A
- TNXP N/A
- EPS
- TRUG N/A
- TNXP N/A
- Revenue
- TRUG $21,917,131.00
- TNXP $11,291,000.00
- Revenue This Year
- TRUG N/A
- TNXP $62.53
- Revenue Next Year
- TRUG N/A
- TNXP $26.17
- P/E Ratio
- TRUG N/A
- TNXP N/A
- Revenue Growth
- TRUG 7.68
- TNXP 183.05
- 52 Week Low
- TRUG $0.35
- TNXP $0.12
- 52 Week High
- TRUG $11.82
- TNXP $14.08
- Technical
- Relative Strength Index (RSI)
- TRUG 44.87
- TNXP 75.02
- Support Level
- TRUG $0.35
- TNXP $0.32
- Resistance Level
- TRUG $0.92
- TNXP $0.72
- Average True Range (ATR)
- TRUG 0.11
- TNXP 0.15
- MACD
- TRUG 0.00
- TNXP 0.04
- Stochastic Oscillator
- TRUG 14.04
- TNXP 39.61
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.